Loading...
Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors
Despite the excellent overall survival (OS) of patients with chronic myeloid leukemia (CML), a significant proportion will not achieve optimal response to imatinib or second-generation tyrosine kinase inhibitors (2GTKI). For patients with inadequate response to 2GTKIs, alternative 2GTKIs or ponatini...
Na minha lista:
| Udgivet i: | J Clin Med |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7408792/ https://ncbi.nlm.nih.gov/pubmed/32679880 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9072251 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|